Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study of Anxiety Free Experiences at the Dentist (SAFE-D)

5 novembre 2026 aggiornato da: Laura Seligman, University of Texas Rio Grande Valley

One Session Treatment for Dental Phobia in an Underserved Population

The goal of this clinical trial is to compare two treatments for dental phobia in children and adolescents: One-Session Treatment for Dental Phobia (OSTD) and psychoeducation plus relaxation training (RELAX).

The main questions this study aims to answer are:

  • Is one intervention more effective in reducing the severity of dental phobia 6 months after treatment?
  • Are improvements in dental fear and anxiety maintained 12 months after treatment?
  • How do changes in fear-related learning and beliefs contribute to treatment outcomes?
  • How acceptable and practical are these treatments for youth, their parents, and the professionals delivering the treatments?

Researchers will enroll approximately 160 youth with dental phobia and randomly assign them to one of two treatment groups. Participants will receive either OSTD or RELAX.

Participants will:

  • Complete an initial assessment of their dental fear and anxiety.
  • Participate in their assigned treatment.
  • Complete assessments 1 week, 6 months, and 12 months after treatment to evaluate changes in dental fear, anxiety, and related beliefs and behaviors.

Researchers will compare the two groups to determine which treatment is more effective in reducing dental phobia, whether improvements last over time, and how changes in fear-related learning may contribute to treatment outcomes.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The study will examine inhibitory learning as a potential mechanism underlying improvements in dental phobia following One-Session Treatment for Dental Phobia (OSTD) compared with psychoeducation and relaxation training (RELAX). Inhibitory learning involves developing new associations that reduce the influence of previously learned fear responses. The study will investigate whether changes in implicit associations with dental-related stimuli and beliefs about potential harm help explain treatment-related improvements in dental phobia.

Exploratory analyses will examine potential predictors and moderators of treatment outcomes at 6 and 12 months post-treatment. Variables of interest include coping efficacy, habituation, fear activation, acculturation, outcome expectancy, fear of pain, cognitive vulnerability, comorbidity, and distress tolerance. Multiple regression models will evaluate associations between these variables and treatment outcomes, including dental phobia severity, dental anxiety symptoms, individualized treatment goal attainment, and dental cleaning appointment attendance. Selected analyses will be restricted to participants receiving OSTD when the predictor is specific to that intervention. Additional analyses will examine whether baseline characteristics moderate differences in treatment outcomes between OSTD and RELAX.

Tipo di studio

Interventistico

Iscrizione (Stimato)

160

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: SAFE-D Research Team Member
  • Numero di telefono: 956-665-3500
  • Email: safe-d@utrgv.edu

Luoghi di studio

    • Texas
      • Brownsville, Texas, Stati Uniti, 78520
        • Non ancora reclutamento
        • University of Texas Rio Grande Valley
        • Contatto:
          • SAFE-D Study Team Member
          • Numero di telefono: 956-665-3500
          • Email: safe-d@utrgv.edu
      • Edinburg, Texas, Stati Uniti, 78539
        • Reclutamento
        • University of Texas Rio Grande Valley
        • Contatto:
          • SAFE-D Study Team Member
          • Numero di telefono: 956-665-3500
          • Email: safe-d@utrgv.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 7 anni a 16 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all the following criteria:

  • Subject and one parent/LAR must be willing and able to give informed assent/consent for participation in the study.
  • Subject and one parent/LAR must be willing and able to comply with all study procedures for the duration of the study, including randomization to treatment condition and interventionist.
  • Subject must be between 7 and 16 years of age.
  • Subject must meet DSM 5 criteria for a specific phobia, blood- injection -injury type with dental stimuli as the focus of the phobia.
  • Subject and parent/LAR must be able to read, write, and converse in English or Spanish.

Exclusion Criteria:

An individual who meets any of the following criteria at baseline will be excluded from participating in this study:

If the parent-reports:

  • Subject or first degree relative participated in the pilot study (UG3DE031247).
  • Subject has active suicidal ideation, psychotic disorder, intellectual disability (as indicated by school placement), or severe autism spectrum disorder.
  • Subject's dental fears are limited to fear of injections or sight of blood.
  • Subject resides in the same household as another individual already participating in current study.
  • Subject is a first degree relative of another individual already participating in current study.
  • Subject has received a trial of exposure therapy or relaxation treatment for dental phobia in the past year.
  • Subject is currently taking anxiolytic medication, and the dose or medication is likely to change between Baseline Assessment and Six-Month Post Treatment Assessment.
  • Any other significant disease or disorder that would place the subject at risk because of participation in the study or preclude the subject's full compliance with or completion of the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: OSTD

OSTD is a cognitive behavioral treatment with the main component of the treatment being massed exposure exercises guided by an inhibitory learning framework.

OSTD is a single-session behavioral intervention designed to reduce dental phobia in children and adolescents. The intervention uses individualized, graduated exposure to feared dental situations and procedures. Exposure activities are guided by a participant-specific fear hierarchy and cognitive-behavioral assessment developed before treatment. During the treatment session, participants engage in exposure exercises intended to help them confront feared dental situations and develop new learning about anticipated negative outcomes.

Comparatore attivo: RELAX

RELAX is a psychoeducational intervention paired with progressive muscle relaxation.

RELAX is a single-session behavioral comparison intervention consisting of psychoeducation and relaxation training for children and adolescents with dental phobia. The intervention includes information about dental-related fear and anxiety and instruction in relaxation strategies, including progressive muscle relaxation. Participants receive guided relaxation training intended to support the management of anxiety associated with dental situations.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Dental Phobia Severity From Baseline to 6 Months Post-Treatment
Lasso di tempo: 6 months post-treatment

Dental phobia severity will be assessed using the dental phobia module of the Anxiety Disorders Interview Schedule for Children. Information obtained from parent and child interviews will be used to establish a consensus Clinician Severity Rating (CSR). The primary outcome is the consensus CSR at 6 months post-treatment. Score range is 0 to 8, lower scores indicate less severe dental phobia. Treatment group differences will be evaluated using regression analysis adjusting for baseline CSR and prespecified covariates.

6 months post-treatment
Change in Dental Phobia Severity From Baseline to 12 Months Post-Treatment
Lasso di tempo: 12 months post-treatment

Dental phobia severity will be assessed using the dental phobia module of the Anxiety Disorders Interview Schedule for Children. Parent and child interview information will be used to establish a consensus Clinician Severity Rating (CSR). Score range is 0 to 8, lower scores indicate less severe dental phobia. The 12-month consensus CSR will be compared between treatment groups, adjusting for baseline CSR and prespecified covariates.

12 months post-treatment
Change in Dental Anxiety Symptoms From Baseline to 12 Months Post-Treatment
Lasso di tempo: 1 week, 6 months, and 12 months post-treatment

Dental anxiety symptoms will be assessed using the Modified Child Dental Anxiety Scale (MCDAS) and a modified parent version (MDAS-P) administered to children and parents. Scores will be used to evaluate dental anxiety at 1 week, 6 months, and 12 months post-treatment. Treatment group differences will be evaluated at each follow-up assessment using regression models adjusting for baseline dental anxiety and prespecified covariates. Higher scores indicate greater dental anxiety.

1 week, 6 months, and 12 months post-treatment
Attainment of Personalized Treatment Goal at 6 Months and 12 Months Post Treatment
Lasso di tempo: 6 months and 12 months post-treatment

Treatment goal attainment will be evaluated using a personalized treatment goal identified by the participant's family. Goal attainment will be classified into three ordered categories: no attainment, partial attainment, and full attainment. Treatment group differences will be evaluated using ordinal regression models.

6 months and 12 months post-treatment
Attendance at Recommended Dental Cleaning Appointment
Lasso di tempo: 6 months and 12 months post-treatment

Compliance with dental health treatment recommendations will be assessed by determining whether the participant attended a recommended dental cleaning appointment. Attendance will be recorded as a binary outcome (attended or did not attend). Treatment group differences will be evaluated at the 6-month and 12-month follow-up assessments.

6 months and 12 months post-treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Implicit Associations With Dental Stimuli Assessed by the Affect Misattribution Procedure (AMP)
Lasso di tempo: Baseline (within 14 days before treatment), Treatment (Day 0), 1 week post-treatment, and 6 months post-treatment

Implicit associations with dental-related stimuli will be assessed using the Affect Misattribution Procedure (AMP). AMP performance will be examined as an indicator of inhibitory learning and evaluated as a potential mediator of treatment outcomes. The measure will be assessed before treatment and at subsequent assessment points to examine treatment-related changes in automatic affective responses to dental stimuli.

Baseline (within 14 days before treatment), Treatment (Day 0), 1 week post-treatment, and 6 months post-treatment
Change in Outcome Expectancy Violation from Baseline to 6 Months Post-Treatment
Lasso di tempo: Baseline (within 14 days before treatment), Treatment (Day 0), 1 week post-treatment, and 6 months post-treatment

Beliefs about potential harm associated with dental treatment will be assessed using the Harm Beliefs component of the Harm Beliefs and Coping Efficacy Interview. Changes in harm beliefs will be evaluated as an indicator of outcome expectancy violation and examined as a potential mediator of treatment outcomes. Perceived Likelihood (Probability): Rating how certain the participant is that a worst-case scenario will happen (from 0 Not Going to Happen to 8 Definitely Going to Happen). Perceived Severity (Impact): Rating the magnitude of the anticipated danger (from 0 Not Bad at All to 8 Very, Very Bad).

Baseline (within 14 days before treatment), Treatment (Day 0), 1 week post-treatment, and 6 months post-treatment

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Parent-Reported Treatment Satisfaction
Lasso di tempo: 1 week, 6 months, and 12 months post-treatment

Parent satisfaction with the assigned treatment will be assessed using the parent version of the Treatment Satisfaction Survey. Scores will be compared between OSTD and RELAX at each follow-up assessment to evaluate parent-reported treatment satisfaction. Scores range from 12-60 with higher scores indicating more satisfaction.

1 week, 6 months, and 12 months post-treatment
Child-Reported Treatment Satisfaction
Lasso di tempo: 1 week, 6 months, and 12 months post-treatment

Child satisfaction with the assigned treatment will be assessed using the child version of the Treatment Satisfaction Survey. Scores will be compared between OSTD and RELAX at each follow-up assessment to evaluate child-reported treatment satisfaction. Scores range from 12-60 with higher scores indicating more satisfaction.

1 week, 6 months, and 12 months post-treatment
Interventionist-Reported Treatment Satisfaction
Lasso di tempo: Within 6 months of completion of treatment delivery for all study participants

Interventionists will complete the Acceptability of Intervention Measure (AIM) to evaluate their perceptions of treatment acceptability. Scores will be compared between OST-D and RELAX to assess differences in perceived acceptability. Interventionists will complete the Feasibility of Intervention Measure (FIM) to evaluate their perceptions of the feasibility of delivering the treatment. Scores will be compared between OST-D and RELAX to assess differences in perceived treatment feasibility. Interventionists will complete the Intervention Appropriateness Measure (IAM) to evaluate their perceptions of the appropriateness of the treatment for youth with dental phobia. Scores will be compared between OST-D and RELAX. Scores range from 4-20 with higher scores indicating greater acceptability, feasibility and appropriateness for each respective measure.

Within 6 months of completion of treatment delivery for all study participants
Treatment Fidelity and Interventionist Competence
Lasso di tempo: Treatment (Day 0)

Treatment fidelity and interventionist competence will be assessed using the study-specific Fidelity and Competence Coding Form. Selected treatment sessions will be evaluated to assess adherence to the assigned intervention protocol and competence in treatment delivery. 25% of sessions in each condition will be coded for fidelity and competence.

Treatment (Day 0)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Laura D Deligman, Ph.D., University of Texas Rio Grande Valley
  • Investigatore principale: Joseph H Hovey, Ph.D., University of Texas Rio Grande Valley

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 marzo 2030

Completamento dello studio (Stimato)

1 marzo 2030

Date di iscrizione allo studio

Primo inviato

20 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 novembre 2026

Primo Inserito (Effettivo)

12 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 22-113-E
  • 4UH3DE031247-03 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .